Processing...
Clinical Trials for Ovarian Cancer
Search
Search
There are 204 active trials for advanced/metastatic ovarian cancer.
Click on a trial to see more information.
204 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial enrolls adults with advanced, recurrent, or metastatic solid tumors (including platinum-resistant ovarian cancer, triple-negative breast cancer, squamous cell carcinoma of the anus or head and neck, non-small cell lung cancer, and uterine serous cancer) who have progressed on all standard therapies, to receive SMP-3124LP, a novel liposomal CHK1 inhibitor given by intravenous infusion. SMP-3124LP targets the DNA damage response pathway and is being assessed for safety, tolerability, and preliminary efficacy.
ClinicalTrials.gov ID: NCT06526819
TrialFetch AI summary: This trial enrolls adults with recurrent, unresectable, locally advanced, or metastatic solid tumors—including colorectal, pancreatic, NSCLC, ovarian cancer, mesothelioma, and others—that express mesothelin (MSLN) and have lost HLA-A*02 expression, who are heterozygous for HLA-A*02. Eligible patients receive a single infusion of A2B694, an autologous CAR T-cell therapy engineered with a logic-gated Tmod system to selectively target MSLN-positive, HLA-A*02-negative tumor cells.
ClinicalTrials.gov ID: NCT06051695
TrialFetch AI summary: This trial enrolls adults with metastatic, measurable solid tumors (including GI, GU, breast, ovarian, endocrine tumors, NSCLC, and multiple myeloma with plasmacytomas) who have progressed after standard therapies, and treats them with autologous T-cells genetically engineered to express T-cell receptors targeting patient-specific tumor neoantigens, following lymphodepletion, with or without the addition of pembrolizumab. The investigational TCR therapy directly targets mutated or viral antigens unique to each patient’s cancer in an effort to induce durable tumor regression.
ClinicalTrials.gov ID: NCT03412877
TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
TrialFetch AI summary: Eligible patients are adults with advanced, folate receptor alpha–expressing solid tumors—including ovarian, endometrial, cervical, non-small cell lung, triple-negative breast, pancreatic, or colorectal cancer—without uncontrolled CNS metastases or significant comorbidities. Treatment involves investigational LY4170156, a topoisomerase I inhibitor antibody-drug conjugate targeting FRα, given as monotherapy or combined with bevacizumab or carboplatin.
ClinicalTrials.gov ID: NCT06400472
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic solid tumors—especially those with CCNE1-amplified ovarian, endometrial, gastric/GEJ, or esophageal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, or HR+ HER2- breast cancer post-CDK4/6 inhibitor—who have exhausted standard therapies, receiving oral NKT3964, a selective CDK2 PROTAC degrader targeting the CDK2/cyclin E pathway.
ClinicalTrials.gov ID: NCT06586957
TrialFetch AI summary: Adults with unresectable, advanced, or metastatic solid tumors (including NSCLC, colorectal, HNSCC, pancreatic, ovarian, or breast cancer) that are both HLA-A*02:01 positive and harbor the TP53 R175H mutation, and who have progressed on prior therapy, may receive NT-175, an autologous T cell product genetically engineered with a TCR targeting TP53 R175H and rendered resistant to TGF-β mediated immunosuppression. Treatment includes leukapheresis, lymphodepletion (fludarabine/cyclophosphamide), NT-175 infusion, and short-course subcutaneous IL-2.
ClinicalTrials.gov ID: NCT05877599
TrialFetch AI summary: Adults with advanced solid tumors—such as high grade serous ovarian, squamous NSCLC, triple negative breast, gastric, colorectal, esophageal, bladder, head and neck, and select gynecologic cancers—who have progressed on standard therapies receive oral VLS-1488, a selective inhibitor of the mitotic kinesin KIF18A, given in 28-day cycles. Patients with active CNS metastases, prior KIF18A inhibitor exposure, or MSI-H/dMMR tumors are excluded.
ClinicalTrials.gov ID: NCT05902988
TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors expressing Nectin-4 who have progressed after or are ineligible for standard systemic therapy, excluding those with brain metastases or serious comorbidities. Patients receive IPH4502, a novel antibody-drug conjugate targeting Nectin-4 with an exatecan payload, administered as monotherapy.
ClinicalTrials.gov ID: NCT06781983
TrialFetch AI summary: Eligible patients are adults with advanced, refractory solid tumors (including soft-tissue sarcoma, triple-negative breast cancer, NSCLC, cervical cancer, ovarian cancer, or KRAS-mutant pancreatic ductal adenocarcinoma), who have not previously received anthracyclines. The trial investigates Spedox-6, a novel human serum albumin-encapsulated doxorubicin formulation designed to enhance tumor delivery and reduce cardiotoxicity, given IV every 21 days at escalating doses (with filgrastim support at higher doses).
ClinicalTrials.gov ID: NCT07064018